The gastrointestinal pharmacology of cannabinoids: focus on motility
- PMID: 22699400
- DOI: 10.1159/000339072
The gastrointestinal pharmacology of cannabinoids: focus on motility
Abstract
The marijuana plant Cannabis sp. and its derivatives and analogues, known as cannabinoids (CBs), induce many effects throughout the whole body. Herein we briefly review the gastrointestinal (GI) pharmacology of CBs, with special focus on motor function. Some drugs are available to treat nausea and emesis, and evidences in humans and animal models suggest that other GI motility alterations (gastro-oesophageal reflux, inflammatory bowel conditions or paralytic ileus) might benefit from modifications of the CB tone throughout the gut. However, central and peripheral (including GI) side effects may occur upon acute and chronic CB administration. Hopefully, the ongoing worldwide intense research on CBs will soon provide new, safer CB-based medicines.
Copyright © 2012 S. Karger AG, Basel.
Similar articles
-
Cannabinoids and the gut: new developments and emerging concepts.Pharmacol Ther. 2010 Apr;126(1):21-38. doi: 10.1016/j.pharmthera.2009.12.005. Epub 2010 Feb 1. Pharmacol Ther. 2010. PMID: 20117132 Review.
-
The gastrointestinal pharmacology of cannabinoids: an update.Curr Opin Pharmacol. 2004 Dec;4(6):572-9. doi: 10.1016/j.coph.2004.05.007. Curr Opin Pharmacol. 2004. PMID: 15525546 Review.
-
Cannabinoids and gastrointestinal motility: animal and human studies.Eur Rev Med Pharmacol Sci. 2008 Aug;12 Suppl 1:81-93. Eur Rev Med Pharmacol Sci. 2008. PMID: 18924447 Review.
-
Cannabinoid pharmacology and therapy in gut disorders.Biochem Pharmacol. 2018 Nov;157:134-147. doi: 10.1016/j.bcp.2018.07.048. Epub 2018 Aug 2. Biochem Pharmacol. 2018. PMID: 30076849 Review.
-
Gut feelings about the endocannabinoid system.Neurogastroenterol Motil. 2011 May;23(5):391-8. doi: 10.1111/j.1365-2982.2011.01689.x. Neurogastroenterol Motil. 2011. PMID: 21481098
Cited by
-
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.Br J Pharmacol. 2015 May;172(9):2406-18. doi: 10.1111/bph.13069. Epub 2015 Feb 27. Br J Pharmacol. 2015. PMID: 25572435 Free PMC article.
-
Cannabinoids and GI Disorders: Endogenous and Exogenous.Curr Treat Options Gastroenterol. 2016 Dec;14(4):461-477. doi: 10.1007/s11938-016-0111-1. Curr Treat Options Gastroenterol. 2016. PMID: 27699625 Review.
-
Cannabinoid hyperemesis syndrome in pregnancy: a case series and review.Obstet Med. 2024 Dec 24:1753495X241307415. doi: 10.1177/1753495X241307415. Online ahead of print. Obstet Med. 2024. PMID: 39759763 Free PMC article.
-
In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.Neurogastroenterol Motil. 2015 Dec;27(12):1721-35. doi: 10.1111/nmo.12668. Epub 2015 Sep 20. Neurogastroenterol Motil. 2015. PMID: 26387676 Free PMC article.
-
Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation.Br J Pharmacol. 2015 Jun;172(12):3099-111. doi: 10.1111/bph.13114. Epub 2015 Apr 23. Br J Pharmacol. 2015. PMID: 25684407 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources